Health & Medicine
A Pill Against the Deadliest Cancer: Daraxonrasib Shrinks Tumors in Six of 10 Newly Diagnosed Pancreatic Patients, and Scans Go Clear for One in 12
New first-line results presented Friday build on the FDA's August approval of the first RAS-targeted pancreatic cancer drug. Here is what the numbers show, what they don't, and what families should ask next.
By SAMUEL ADEYEMIStaff Correspondent · WASHINGTON · Nov 20, 7:00 AM · 5 min. read

Illustration · Liberty Bell Report
For families who have heard the words "pancreatic cancer" in a doctor's office, hope has usually come in small portions. On Friday it came in a larger one. Updated results from an early-stage study showed that a once-daily pill called daraxonrasib, taken alongside standard chemotherapy as the very first treatment, shrank tumors in about six of every 10 patients whose cancer had already spread, and left no visible cancer on scans in roughly one in 12.
The BBC described the drug as appearing to shrink, and possibly even eliminate, tumors in some patients with one of the deadliest cancers. The excitement is warranted. So is a careful reading of the numbers, because this is a study of 61 people, not yet the large head-to-head trial that settles a medical question.
What the New Numbers Show
The results were presented Friday in a plenary session by investigator Wungki Park as a late-breaking abstract on daraxonrasib combined with gemcitabine and nab-paclitaxel, the chemotherapy pairing known as GnP, as first-line treatment for metastatic pancreatic adenocarcinoma, the most common form of the disease.
According to the update reported from the drug's maker, Revolution Medicines, 61 patients were evaluated as of Sept. 28, 2026, with a median follow-up of 18.3 months. The confirmed objective response rate, the share of patients whose tumors shrank by a set, measurable amount, was 60.7 percent. The complete response rate, meaning no visible cancer remained on scans, was 8.2 percent.
The other measures pointed the same direction. The disease control rate, which counts patients whose tumors shrank or simply stopped growing, was 90.2 percent. The median duration of response was 11.1 months, median progression-free survival was 12.8 months, and 76.6 percent of patients were still alive one year in.
Those terms deserve a plain-English translation. Progression-free survival is how long patients live before their cancer grows or spreads, so a median of 12.8 months means half the patients in the study went longer than that without their disease advancing. One-year survival of 76.6 percent means roughly three in four patients were alive a year after starting treatment. Late-breaking abstracts are typically reserved for results organizers consider too important to wait for the next meeting, and plenary sessions are the main stage of a scientific conference, which says something about how seriously the field is taking this work.
Tolerability matters as much as response in a disease where patients are often frail. About 5 percent of patients stopped treatment because of side effects tied to daraxonrasib, according to the release on the study.
The Drug Behind the Headlines
Friday's study builds on a regulatory milestone. In late August the Food and Drug Administration approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma whose disease progressed after at least one prior systemic therapy, or who are not candidates for multi-drug chemotherapy.
The agency based that decision on the Phase 3 RASolute 302 trial, which randomly assigned patients to daraxonrasib or standard chemotherapy. Median overall survival was 13.2 months with daraxonrasib, compared with 6.7 months with chemotherapy. For a cancer where extra weeks are hard won, nearly doubling median survival in patients whose first treatment had already failed was a major result.
The FDA said it approved the application about six and a half months ahead of its goal date, and the drug carries breakthrough therapy and orphan drug designations. The recommended dose is 300 milligrams taken by mouth once a day, until the disease progresses or side effects become intolerable.
The American Association for Cancer Research called daraxonrasib the first pan-RAS inhibitor approved for any type of cancer. RAS proteins act as on-off switches for cell growth, and in many tumors they are stuck in the "on" position. The AACR explained that the drug works by bridging RAS with a helper protein called cyclophilin A, shutting down the active form of the protein.
That is why Friday's first-line data drew so much attention. The August approval covers patients later in their illness. The new study asks whether giving the pill at the start, together with chemotherapy, changes the course of the disease from day one.
Why Pancreatic Cancer Has Been So Hard to Beat
Pancreatic cancer has resisted most of the advances of the last generation. The American Cancer Society's 2026 report put the five-year relative survival rate at 13 percent, unchanged for a third straight year, according to the Lustgarten Foundation's summary of the report. Only about 17 percent of patients are diagnosed while the cancer is still confined to the pancreas, when five-year survival is 44 percent.
Put plainly, most patients are found late. By the time symptoms appear, the cancer has often spread, surgery is off the table, and treatment becomes a fight for time. A first-line response rate above 60 percent, with nine in 10 patients seeing their disease held in check, is the kind of signal oncologists have waited years to see in this disease.
There is also a practical difference in how the drug is given. Daraxonrasib is a pill taken at home once a day. For patients already spending long hours in infusion chairs for chemotherapy, a targeted treatment that comes in a bottle is not a small thing.
Reasons for Patience
The case for hope has to include the case for patience.
First, 61 patients is a small group. Early-phase studies are built to test safety and give a first look at how well a treatment works. The definitive test is the Phase 3 RASolute 303 trial, now under way in patients who have not yet been treated, which the company cites the new data as supporting.
Second, a complete response on a scan is not the same as a cure. Imaging can miss very small amounts of disease, and what matters most over time is how long responses last. In this study, the median response lasted 11.1 months. That is meaningful in pancreatic cancer, but it also means many patients' cancers eventually began growing again.
Third, the drug has real side effects. The FDA's label carries warnings for skin and soft-tissue toxicity, mouth sores, diarrhea, gastrointestinal perforation, lung inflammation, and harm to an unborn baby. Women who are pregnant or could become pregnant, and anyone with a history of lung or bowel problems, should talk those risks through with their doctor before starting treatment.
What Comes Next for Patients and Families
For patients diagnosed today, the most useful questions are practical ones. Does daraxonrasib fit under the FDA's current approval, which covers patients whose disease has progressed after earlier treatment or who cannot take multi-drug chemotherapy? Is a trial of first-line use enrolling nearby? And what side effects should the family watch for at home?
The answers will differ from patient to patient, and only a treating oncologist can give them. But families no longer have to walk into that conversation with nothing new to ask about.
Science moves slowly, and it moves through ordinary people who volunteer for trials, doctors who keep searching, and families who keep praying. Friday's numbers are early. They are also the most encouraging news this disease has produced in a long time, and they are worth giving thanks for while the larger trial does its work.
Sources
- EurekAlert: Metastatic pancreatic cancer responds well to initial treatment with combination of daraxonrasib and chemotherapy (link)
- Investing.com: Revolution Medicines reports updated pancreatic cancer trial data (link)
- BBC News: Massive hope for pancreatic cancer pill after trial saw tumours vanish (link)
- U.S. Food and Drug Administration: FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma (link)
- Lustgarten Foundation: New Report: ACS Cancer Facts & Figures 2026 report five-year relative survival rate for pancreatic cancer remains at 13% (link)
- AACR: FDA Approves Daraxonrasib as First RAS Inhibitor for Pancreatic Cancer (link)
— 30 —


